ArticleMicrobial cell factories2026
Antibacterial potential, DNA binding and molecular docking investigations of newly green synthesized zinc oxide/chitosan/vancomycin nanocomposite using Bacillus licheniformis ATCC 4527 against some drug-resistant bacteria.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Allium cepa mediated green synthesis of ZnO nanoparticles with antibacterial antibiofilm and synergistic activity against uropathogenic multidrug resistant Escherichia coli.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing crisis of multidrug-resistant (MDR) bacteria requires the creation of new, highly effective, and safe antibacterial agents. This study introduces a simple and cost-effective green synthesis method for a novel zinc oxide/chitosan/vancomycin (ZnO/CS/VA) nanocomposite to improve antibacterial activity against priority MDR strains. Zinc oxide nanoparticles (ZnO NPs) were biosynthesized using Bacillus licheniformis ATCC 4527 and then combined with vancomycin (VA) and chitosan (CS) in an environmentally friendly process. Transmission electron microscopy (TEM), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), ultraviolet-visible spectroscopy (UV-Vis), and zeta potential studies were conducted to validate and characterize the production of ZnO/CS/VA. The antibacterial activity of the nanoparticles was tested against several multidrug-resistant (MDR) strains, including Bacillus cereus HES3, methicillin-resistant S. aureus (MRSA), Escherichia coli D8, Pseudomonas aeruginosa, and Klebsiella pneumoniae H4. Further assessment included molecular docking interactions with E. coli (PDB: 3T88) and MRSA (PDB: 4DKI) targets, CT-DNA binding, and cytotoxicity testing on the Vero cell line. Characterization confirmed the successful formation of the nanocomposite, revealing ZnO nanoparticles ranging from 33.24 to 69.11 nm and high stability (zeta potential: -17.78 mV). The ZnO/CS/VA nanocomposite exhibited superior dose-dependent antibacterial activity compared to ZnO nanoparticles or VA alone against all tested MDR strains, including MRSA and E. coli D8. Molecular docking demonstrated strong binding, with scores ranging from -0.7 to -10.85 kcal/mol. The nanocomposite exhibited a hypochromism when interacting with CT-DNA, suggesting intercalation. Importantly, the CC50 values of ZnO NPs and ZnO/CS/VA against Vero cells were 146.62±1.03 and 162.86±1.07 μg/mL, respectively, indicating their high level of safety.
conclusionsThe green-synthesized ZnO/CS/VA nanocomposite is a promising alternative candidate for treating various MDR bacterial infections. It offers utility in biomedical and pharmaceutical applications due to its high efficacy and low cytotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.